Passage BIO, Inc. (PASG) stock
PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.25+0.24 (+5.99%)
Close on Nov 13, 2026Market cap $13.68MP/E –Yield –
Passage BIO r&d expenses
Research and development expenses are spending on new products and technology.
Passage BIO's R&D Expenses for the twelve months ending Sep 30, 2026 was $14.35M, down 47.7% year over year. For fiscal 2025 it was $23.28M, down 42.1% from the year before. The highest annual figure on record is $117.67M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.28M | -42.1% |
| FY2024 | Dec 31, 2024 | $40.18M | -34.6% |
| FY2023 | Dec 31, 2023 | $61.42M | -28.6% |
| FY2022 | Dec 31, 2022 | $86.05M | -26.9% |
| FY2021 | Dec 31, 2021 | $117.67M | +43.9% |
| FY2020 | Dec 31, 2020 | $81.79M | +175.0% |
| FY2019 | Dec 31, 2019 | $29.74M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.50M | -65.2% |
| Q2 FY2026 | Jun 30, 2026 | $3.34M | -42.5% |
| Q1 FY2026 | Mar 31, 2026 | $4.09M | -47.1% |
| Q4 FY2025 | Dec 31, 2025 | $5.42M | -43.3% |
| Q3 FY2025 | Sep 30, 2025 | $4.31M | -50.2% |
| Q2 FY2025 | Jun 30, 2025 | $5.81M | -44.3% |
| Q1 FY2025 | Mar 31, 2025 | $7.74M | -32.9% |
| Q4 FY2024 | Dec 31, 2024 | $9.56M | -21.4% |
| Q3 FY2024 | Sep 30, 2024 | $8.66M | -42.7% |
| Q2 FY2024 | Jun 30, 2024 | $10.43M | -39.8% |
| Q1 FY2024 | Mar 31, 2024 | $11.54M | -31.5% |
| Q4 FY2023 | Dec 31, 2023 | $12.16M | -31.1% |
| Q3 FY2023 | Sep 30, 2023 | $15.10M | -1.7% |
| Q2 FY2023 | Jun 30, 2023 | $17.32M | -35.4% |
| Q1 FY2023 | Mar 31, 2023 | $16.84M | -35.8% |
| Q4 FY2022 | Dec 31, 2022 | $17.66M | -46.4% |
| Q3 FY2022 | Sep 30, 2022 | $15.36M | -42.3% |
| Q2 FY2022 | Jun 30, 2022 | $26.82M | -19.0% |
| Q1 FY2022 | Mar 31, 2022 | $26.21M | +5.0% |
| Q4 FY2021 | Dec 31, 2021 | $32.97M | +18.0% |
| Q3 FY2021 | Sep 30, 2021 | $26.62M | +27.8% |
| Q2 FY2021 | Jun 30, 2021 | $33.11M | +66.4% |
| Q1 FY2021 | Mar 31, 2021 | $24.97M | +90.4% |
| Q4 FY2020 | Dec 31, 2020 | $27.93M | +180.1% |
| Q3 FY2020 | Sep 30, 2020 | $20.84M | +99.7% |
| Q2 FY2020 | Jun 30, 2020 | $19.90M | +216.0% |
| Q1 FY2020 | Mar 31, 2020 | $13.12M | – |
| Q4 FY2019 | Dec 31, 2019 | $9.97M | – |
| Q3 FY2019 | Sep 30, 2019 | $10.43M | – |
| Q2 FY2019 | Jun 30, 2019 | $6.30M | – |
See a number that looks wrong?